Depomed Sends Letter to Horizon Pharma

Go back to Depomed Sends Letter to Horizon Pharma

Brean Capital Remains Bullish on Horizon Pharma (HZNP) Following 2Q Beat

August 10, 2015 6:51 AM EDT

Brean Capital reiterated a Buy rating and $40 price target on Horizon Pharma (NASDAQ: HZNP) following the release of its 2Q15 earnings results. revenue was $172.8 million beating consensus estimates of $156.4. Non-GAAP EPS was $0.39 beating consensus' $0.32.

Analyst Difei Yang commented, "Given the pre-announcement of... More

Horizon Pharma (HZNP) Tops Q2 EPS by 7c

August 7, 2015 7:02 AM EDT

Horizon Pharma (NASDAQ: HZNP) reported Q2 EPS of $0.39, $0.07 better than the analyst estimate of $0.32. Revenue for the quarter came in at $172.8 million versus the consensus estimate of $156.41 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

... More

Depomed (DEPO) Sends Letter to Horizon Pharma (HZNP); Will be Open to 'Compelling Proposal'

August 7, 2015 6:32 AM EDT

Depomed (NASDAQ: DEPO) has sent the following letter to Horizon Pharma plc (NASDAQ: HZNP) ("Horizon"):

August 7, 2015

Timothy P. Walbert Chairman of the Board, President and Chief Executive OfficerHorizon Pharma plcConnaught House, 1st Floor, 1 Burlington Road Dublin 4, Ireland

Dear Tim,

In our conversation late last week, you stated that Horizon was prepared to increase its proposal and to... More